Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.53 |
| ▸ | ITGAV | P06756 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | EEF2K | O00418 | 3/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5340108 | 0.95 | ITGB3 (0.59) | ITGB3ITGAVALDH1A1ATML3MBTL1 | |
| SCHEMBL5336087 | 0.88 | ITGB3 (0.60) | ITGB3ITGAVALDH1A1ATML3MBTL1 | |
| SCHEMBL3835824 | 0.81 | ITGB3 (0.52) | ITGB3ITGAVADAMTS4PTPN1 | |
| SCHEMBL3839395 | 0.80 | ITGB3 (0.79) | ITGB3ITGAV | |
| SCHEMBL5338043 | 0.76 | ITGB3 (0.57) | ITGB3ITGAVADAMTS4 | |
| SCHEMBL5340097 | 0.75 | ITGB3 (0.88) | ITGB3ITGAV | |
| SCHEMBL5878235 | 0.73 | ITGB3 (0.89) | ITGB3ITGAV | |
| SCHEMBL7408745 | 0.70 | ITGB3 (0.67) | ITGB3ITGAVALDH1A1ATML3MBTL1 | |
| SCHEMBL5338635 | 0.70 | ITGB3 (0.69) | ITGB3ITGAVADAMTS4 | |
| SCHEMBL5878472 | 0.70 | ITGB3 (0.89) | ITGB3ITGAVALDH1A1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | US | disclosed |
| EP-1219305-A1 | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183256-A1 | Cytostatic-integrin conjugates having specifically cleavable linking units | ITGAV, ITGB3, ITGAL | ITGB3 2/4885ITGAV 1/4885ALDH1A1 2750/4885 |
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | ITGB3 2/4885ITGAV 1/4885ALDH1A1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.